FDA Approves First Biologic for Rare, Debilitating Lung Disease

The U.S. Food and Drug Administration (FDA) approved Genentech’s Actemra (tocilizumab) for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is the first biologic approved by the FDA for this indication.